LU93081I2 - Ambrisentan utilisé en traitement combiné avec tadalafil - Google Patents

Ambrisentan utilisé en traitement combiné avec tadalafil Download PDF

Info

Publication number
LU93081I2
LU93081I2 LU93081C LU93081C LU93081I2 LU 93081 I2 LU93081 I2 LU 93081I2 LU 93081 C LU93081 C LU 93081C LU 93081 C LU93081 C LU 93081C LU 93081 I2 LU93081 I2 LU 93081I2
Authority
LU
Luxembourg
Prior art keywords
ambrisentan
tadalafil
treatment combined
treatment
combined
Prior art date
Application number
LU93081C
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93081(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of LU93081I2 publication Critical patent/LU93081I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU93081C 2006-12-12 2016-05-20 Ambrisentan utilisé en traitement combiné avec tadalafil LU93081I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86966706P 2006-12-12 2006-12-12
PCT/US2007/087058 WO2008073928A1 (fr) 2006-12-12 2007-12-11 Composition de traitement de l'hypertension pulmonaire

Publications (1)

Publication Number Publication Date
LU93081I2 true LU93081I2 (fr) 2016-07-20

Family

ID=39092031

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93081C LU93081I2 (fr) 2006-12-12 2016-05-20 Ambrisentan utilisé en traitement combiné avec tadalafil

Country Status (15)

Country Link
US (7) US20080139593A1 (fr)
EP (2) EP2101777B1 (fr)
JP (1) JP2010512414A (fr)
AU (1) AU2007333115B2 (fr)
CA (1) CA2669536C (fr)
CY (1) CY2016017I1 (fr)
DK (1) DK2101777T3 (fr)
ES (1) ES2544724T3 (fr)
HK (1) HK1218393A1 (fr)
HU (2) HUE025355T2 (fr)
LU (1) LU93081I2 (fr)
PL (1) PL2101777T3 (fr)
PT (1) PT2101777E (fr)
SI (1) SI2101777T1 (fr)
WO (1) WO2008073928A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333115B2 (en) 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
EP2170397A1 (fr) 2007-07-11 2010-04-07 Lexicon Pharmaceuticals, Inc. Procédés et compositions de traitement d'hypertension pulmonaire et de maladies et de troubles apparentés
CA2695259C (fr) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites et derives d'ambrisentan
WO2010062640A1 (fr) * 2008-10-28 2010-06-03 Gilead Colorado, Inc. Procédés de traitement d'une fibrose pulmonaire idiopathique et de complications associées
CA2802891A1 (fr) * 2010-06-30 2012-01-05 Gilead Sciences, Inc. Utilisation d'antagonistes de recepteur d'adenosine a2b pour traiter l'hypertension pulmonaire
SI2637664T1 (sl) * 2010-10-15 2017-07-31 Gilead Sciences, Inc. Sestavki in postopki zdravljenja pljučne hipertenzije
US20140271680A1 (en) * 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20130224306A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating a pulmonary hypertension condition without companion diagnosis
US20130225595A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
WO2014003678A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil
US10518112B2 (en) * 2014-06-18 2019-12-31 Sonivie Ltd. Method for treating secondary pulmonary hypertension
US10576083B2 (en) * 2015-08-13 2020-03-03 Cipla (UK) Limited Method of treating pulmonary arterial hypertension
EP3675840A4 (fr) * 2017-08-30 2021-05-12 Bellerophon Pulse Technologies LLC Utilisation d'oxyde nitrique inhalé pour l'amélioration de la fonction ventriculaire droite et/ou gauche
BR112020012964A2 (pt) * 2017-12-28 2020-12-01 Bellerophon Pulse Technologies Llc uso de óxido nítrico e oxigênio inalados para o tratamento da hipertensão pulmonar
US20220331313A1 (en) * 2019-05-06 2022-10-20 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
CA3161960A1 (fr) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan pour traiter l'hypertension pulmonaire accompagnee d'une insuffisance cardiaque au moyen d'une fraction d'ejection preservee (ph-hfpef)
RU2729033C1 (ru) * 2020-02-03 2020-08-03 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией
WO2021219671A1 (fr) * 2020-04-28 2021-11-04 Noorik Biopharmaceuticals Ag Traitement de complications pulmonaires d'infections à coronavirus
EP3906928A1 (fr) * 2020-05-06 2021-11-10 Noorik Biopharmaceuticals AG Traitement des complications pulmonaires du coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4325525A (en) 1980-11-13 1982-04-20 General Motors Corporation Mounting member
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP2295436A1 (fr) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phényl-substitués Imidazotriatinone comme inhibiteurs de la phosphodiesterase V
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
WO2006007213A1 (fr) * 2004-06-23 2006-01-19 Myogen, Inc. Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
TW200621261A (en) 2004-08-26 2006-07-01 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7511035B2 (en) 2005-01-25 2009-03-31 Glaxo Group Limited Antibacterial agents
DK2013208T3 (da) * 2006-04-21 2011-08-15 Pfizer Prod Inc Pyridin[3,4-B]pyrazinoner
AU2007333115B2 (en) * 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
CA2669535A1 (fr) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Utilisation de l'ambrisentan associe avec un inhibiteur de renine dans les troubles de l'hypertension
CA2695259C (fr) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites et derives d'ambrisentan
WO2010062640A1 (fr) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Procédés de traitement d'une fibrose pulmonaire idiopathique et de complications associées
SI2637664T1 (sl) 2010-10-15 2017-07-31 Gilead Sciences, Inc. Sestavki in postopki zdravljenja pljučne hipertenzije

Also Published As

Publication number Publication date
US20170136016A1 (en) 2017-05-18
US20130116257A1 (en) 2013-05-09
EP2101777A1 (fr) 2009-09-23
US20110245253A1 (en) 2011-10-06
DK2101777T3 (en) 2015-08-17
US9993475B2 (en) 2018-06-12
AU2007333115A1 (en) 2008-06-19
CA2669536A1 (fr) 2008-06-19
CY2016017I2 (el) 2016-10-05
WO2008073928A1 (fr) 2008-06-19
CA2669536C (fr) 2016-05-31
EP2101777B1 (fr) 2015-05-20
US20100152217A1 (en) 2010-06-17
CY2016017I1 (el) 2016-10-05
EP2952193A1 (fr) 2015-12-09
JP2010512414A (ja) 2010-04-22
US20080139593A1 (en) 2008-06-12
SI2101777T1 (sl) 2015-08-31
HUE025355T2 (en) 2016-02-29
US20150224100A1 (en) 2015-08-13
PT2101777E (pt) 2015-09-18
ES2544724T3 (es) 2015-09-03
PL2101777T3 (pl) 2015-10-30
US20140296244A1 (en) 2014-10-02
US9504685B2 (en) 2016-11-29
US8377933B2 (en) 2013-02-19
HUS1600027I1 (hu) 2016-06-28
US9474752B2 (en) 2016-10-25
AU2007333115B2 (en) 2013-01-10
HK1218393A1 (zh) 2017-02-17

Similar Documents

Publication Publication Date Title
LU93081I2 (fr) Ambrisentan utilisé en traitement combiné avec tadalafil
BRPI0810814A2 (pt) Formas sólidas de dosagem incluindo tadalafil
ATE447990T1 (de) Pumpensatz mit sicherer ladefunktion
FIU20060412U0 (fi) Suojaliivi
DE602006011371D1 (de) Infrarot-eindringdetektionseinrichtung
HK1110422A1 (en) Portable crime-preventive buzzer
DK2056953T3 (da) Filterindløb
FR2915997B1 (fr) Traitement anti-graffitis.
BRPI0914337A2 (pt) produto de limpeza enrolado portátil
DK2001499T3 (da) Anvendelse af TGS-6 til behandling af osteoporose
TWI318128B (en) Portable water cleaner
DE602006019048D1 (de) EDDH enthaltende Entzunderungslösungen
IT1391202B1 (it) Esca rodenticida e suo uso.
NO20065018A (no) Stol
FR2903669B3 (fr) 02isse demontable.
FR2904208B1 (fr) Baignoire portable
FR2901326B1 (fr) Appareil de pompage roulant.
DE102009022853A8 (de) Personen-Transportvorrichtung
NL1028154A1 (nl) Vernieuwde toepassing op bestaand textiel dmv het gebruik van losse elementen met klittenband die te fabriceren zijn in de ruimste zin van het woord.
ES1061838Y (es) Escalera portatil.
ITVI20060279A1 (it) Formella multiuso
ES1063811Y (es) Tumbona portatil
ES1067241Y (es) Barbacoa portatil desarmable
UA14482S (uk) Портативний електрокардіограф
ES1062275Y (es) Mochila rodante multifuncion